Literature DB >> 21328439

Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).

Sung-Eun Lee1, Ji-Sun Paik, Won-Kyung Cho, Byung-Ock Choi, Sang-Nam Lee, Seung-Eun Jung, Kyung-Sin Park, Chang-Suk Kang, Sung-Hoon Kim, Suk-Woo Yang, Seok-Goo Cho.   

Abstract

The American Joint Committee on Cancer has proposed the tumor, node, metastasis (TNM) staging system to overcome the limitations of the Ann Arbor staging system for ocular adnexal lymphoma. We performed this study to evaluate the feasibility of the TNM staging system for ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (OAML). The data form 66 total eyes from 54 patients with biopsy-confirmed OAML according to World Health Organization classification were retrospectively analyzed. Using the TNM staging system, we reclassified all patients into two categories: (1) T1N0M0 stage group (n = 26), for patients with lymphoma involving only the conjunctiva; and (2) above T1N0M0 or bT1N0M0 stage group (n = 28), for patients with lymphoma extending to the orbit, eyelid, or adjacent structures, and/or bilateral OAML. After a 24-month median follow-up period for all patients, the T1N0M0 group revealed higher progression-free survival (PFS) than the above T1N0M0 or the bT1N0M0 group (P = 0.041). In a separate analysis of only 50 patients categorized as Ann Arbor stage IE, the T1N0M0 group demonstrated higher PFS (100%) than the above T1N0M0 or the bT1N0M0 group (84.7%; P = 0.067). Our data show that the poor prognostic group classified as Ann Arbor stage IE can be further distinguished by using the TNM staging system. Thus, further studies to develop treatment strategies for reducing relapse after treatment for OAML should use the TNM staging system.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21328439     DOI: 10.1002/ajh.21963

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  Is it Worthwhile to Undergo the Extended Stage Assessment in Orbital and Ocular Adnexal MALT Lymphoma with Symptoms Limited to the Ocular Adnexa?

Authors:  Sungwoo Park; Gyeong-Won Lee; Myung Soo Hyun; Kyung Hee Lee; Sung Ae Koh; Min Kyoung Kim
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-26       Impact factor: 0.900

2.  Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study.

Authors:  Gi-June Min; Sung Eun Kim; Tong Yoon Kim; Young-Woo Jeon; Joo Hyun O; Byung-Ock Choi; Gyeongsin Park; Suk-Woo Yang; Seok-Goo Cho
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

3.  Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.

Authors:  Swathi Kaliki; Adit Gupta; Mohammed Hasnat Ali; Anuradha Ayyar; Milind N Naik
Journal:  Int Ophthalmol       Date:  2016-02-01       Impact factor: 2.031

4.  Risk potentiality of frontline radiotherapy associated cataract in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Won-Kyung Cho; Sung-Eun Lee; Ji-Sun Paik; Seok-Goo Cho; Suk-Woo Yang
Journal:  Korean J Ophthalmol       Date:  2013-07-05

5.  Primary Sjögren's syndrome initially presenting as submandibular mucosa-associated lymphoid tissue lymphoma: A case report.

Authors:  Liang-Yu Chen; Ming-Hsui Tsai; Li-Tai Tsai; Hsin-Man Lu; Chia-Ing Jan
Journal:  Oncol Lett       Date:  2015-11-30       Impact factor: 2.967

6.  Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type.

Authors:  Jung-Ho Kim; Young-Woo Jeon; Byung-Ock Choi; Gyeongsin Park; Yong-Kil Hong; Suk-Woo Yang; Seok-Goo Cho
Journal:  Korean J Intern Med       Date:  2016-09-07       Impact factor: 2.884

7.  Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma.

Authors:  Young-Woo Jeon; Hee-Jung Yang; Byung-Ock Choi; Seung-Eun Jung; Kyung-Sin Park; Joo-Hyun O; Suk-Woo Yang; Seok-Goo Cho
Journal:  EClinicalMedicine       Date:  2018-10-17

8.  Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study.

Authors:  Sung-Yong Kim; Suk-Woo Yang; Won-Sik Lee; Jae Wook Yang; Sung Yong Oh; Hee Bae Ahn; Deok-Hwan Yang; Seong Kyu Park; Jee Ho Chang; Hyo Jung Kim; Min Joung Lee; Seok-Goo Cho
Journal:  Oncotarget       Date:  2017-08-02

9.  Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas.

Authors:  Hye Lim Park; Joo Hyun O; Sonya Youngju Park; Seung-Eun Jung; Gyeongsin Park; Byung-Ock Choi; Sung Hoon Kim; Young-Woo Jeon; Seok-Goo Cho; Suk-Woo Yang
Journal:  EJNMMI Res       Date:  2019-11-21       Impact factor: 3.138

10.  Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review.

Authors:  Hyun Uk Chung; Jun Hyuk Son
Journal:  J Yeungnam Med Sci       Date:  2021-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.